Vaccine Targeting Tumor Antigen to Dendritic Cell Receptors Induces Antigen-Specific Immunity

Get Permission

Anticancer immunity may be enhanced by harnessing the ability of dendritic cells to initiate T-cell immunity through efficient uptake and presentation of endocytosed material. In preclinical models, delivery of tumor-associated antigens to dendritic cells using receptor-specific monoclonal antibodies in the presence of dendritic cell–activating agents has produced marked antigen-specific immune responses.

CDX-1401 is a vaccine consisting of a monoclonal antibody specific for DEC-205, a molecule expressed on dendritic cells that is active in antigen processing and presentation, fused to the full-length tumor antigen NY-ESO-1. In a phase I trial reported in Science Translational Medicine, Dhodapkar and colleagues assessed the safety, immunogenicity, and clinical activity of escalating doses of CDX-1401 along with administration of Toll-like receptor (TLR) agonists resiquimod (TLR7/8) and Hiltonol (poly-ICLC, TLR3) in 45 patients with advanced malignancies refractory to available therapies.

Vaccine was associated with humoral and cellular immunity to NY-ESO-1 in patients with NY-ESO-1–expressing tumors across various dose levels and adjuvant combinations. No dose-limiting or grade 3 toxicities were reported. Stable disease was observed in 13 patients, with a median duration of 6.7 months (range = 2.4+ to 13.4 months), and 2 patients had approximately 20% shrinkage in target lesions. Six of eight patients who received TLR inhibitors within 3 months after vaccine administration had objective tumor regression.

The investigators concluded, “This first-in-human study of a protein vaccine targeting [dendritic cells] demonstrates its feasibility, safety, and biological activity and provides rationale for combination immunotherapy strategies including immune checkpoint blockade.” ■

Dhodapkar NV, et al: Sci Transl Med 6:232ra51, 2014.

Lab Notes is compiled and written for The ASCO Post by Matthew Stenger.






By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.